Sweden's MedCap Q2 net sales rise 16% on organic growth and acquisitions
Sweden's MedCap Q2 net sales rise 16% on organic growth and acquisitions
Overview
Sweden-based life sciences investor's Q2 net sales rose 16%, driven by organic growth and acquisitions
Adjusted EBITA increased 28%, with margin rising to 20.5% from 18.7%
Recent acquisitions, including Biopsafe and XGX Pharma, contributed to growth and margin improvement
Outlook
Company expects acquisition opportunities to remain favourable and plans further acquisitions
Specialty Pharma earnings and margin expected to strengthen as newer products grow
Result Drivers
ORGANIC GROWTH - Co said strong organic growth in several businesses, particularly MedTech, supported Q2 results
ACQUISITIONS - Recent acquisitions, including Biopsafe, LivAssured and XGX Pharma, contributed to sales and margin growth
PRODUCT MIX - Favourable product mix at Abilia in Assistive Tech business area supported net sales growth
Company press release: ID:nMFN3TRN3z
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue |
| SEK 606.30 mln |
|
Q2 EPS |
| SEK 4.60 |
|
Q2 Net Income |
| SEK 69.10 mln |
|
Analyst Coverage
The one available analyst rating on the shares is "buy"
The average consensus recommendation for the investment management & fund operators peer group is "buy"
Wall Street's median 12-month price target for MedCap AB (publ) is SEK617.50, about 23.8% above its July 20 closing price of SEK498.60
The stock recently traded at 26 times the next 12-month earnings vs. a P/E of 23 three months ago
Reuters Recommended Reads
July 20 - Sweden's Devyser Diagnostics Q2 sales fall on distributor inventory adjustment
July 20 - Sweden's Advenica posts Q2 operating loss on weak product sales
July 20 - Scholar Rock says EU opinion on SMA drug may be pushed to later in 2026
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)